Fully enrolled and not recruiting for Phase 1/2 Study
We are fully enrolled and not recruiting for a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants.
The FDA has approved the U.S. IND (IND 154637) and granted Orphan Drug Designation for SPG302 for the treatment of ALS.
Clinical Trial Sites are Fully Enrolled in Australia:
NCT05882695 Status: Active, not recruiting
Locations Dr. Schultz at Flinders Medical Center in Adelaide, SA.
Dr Henderson at the Royal Brisbane and Woman’s Hospital in Brisbane, Queensland
Dr Rowe at Macquarie Hospital in North Ryde, N.S.W.